Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
Part of Cancer, Immune system & allergy, Infections clinical trials.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have KS confirmed by a pathology lab (biopsy-proven Kaposi sarcoma).
- Your KS needs treatment with medicines (either widespread disease or it affects quality of life), or it has not responded to prior systemic therapy.
- You must have at least five skin KS spots that can be measured and have not had local radiation or local spot-killing treatments.
- If you had prior KS treatment, you need time for side effects to improve and a washout from chemo or immunotherapy before starting.
- If you have HIV, you must be on HIV treatment (ART) for at least 8 weeks with controlled viral load and enough immune cells (CD4).
- You must meet blood tests and organ function limits, and you must be able to sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
This study follows people with Kaposi sarcoma to learn more about the disease and how it changes over time. It may help doctors better understand and treat KS in the future.
This trial compares two chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, to see which works better for HIV-related Kaposi sarcoma. It aims to find a more effective treatment to shrink skin lesions and improve quality of life.
This trial tests whether propranolol, a beta-blocker medicine, can treat Kaposi sarcoma (KS), a type of cancer that causes lesions on the skin or mouth. It may help people with mild-to-moderate KS, including those with HIV, if their disease has not improved or has worsened despite other treatments.
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.